The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InHoth Therapeutics (HOTH) announced positive results from its clinical study of HT-001, a topical treatment for skin toxicities in cancer patients undergoing EGFR therapy. The data revealed a significant 77% increase in drug exposure while maintaining minimal systemic absorption. Crucially, systemic levels were approximately 99% lower than those found in FDA-approved oral formulations, significantly reducing potential side effects. No serious adverse events or dose-limiting toxicities were reported during the study, confirming a strong safety profile for the candidate. This milestone validates the company's approach to providing effective local treatment without the risks associated with systemic therapies. Investors view these results as a positive step forward for the company's oncology pipeline and its long-term growth potential.